Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
Brief Summary: The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
C: Arm Label: Tocilizumab 8 mg/kg + DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Permitted DMARDs | Arm Label: Placebo + DMARDs; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Permitted DMARDs | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg + DMARDs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + DMARDs | Intervention Type: DRUG; Name: Permitted DMARDs; Assigned to Arm(s): Placebo + DMARDs, Tocilizumab 8 mg/kg + DMARDs
D: Arm Label: CDP6038 60 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 60 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tocilizumab (Actemra or RoActemra), Other: Placebo sc | Arm Label: Placebo sc every 2 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Arm Label: Placebo sc every 4 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: Tocilizumab (Actemra or RoActemra); Assigned to Arm(s): Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate, Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo iv; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate, CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 2 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 2 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate, Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate

Answer: A